SWA
CRBP icon

SFMG Wealth Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

SFMG Wealth Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-370
Closed -$56K – 145
2018
Q2 		$56K Hold
370
– – 0.01% 151
2018
Q1 		$68K Hold
370
– – 0.01% 149
2017
Q4 		$79K Buy
+370
New +$79.2K 0.01% 142

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

SFMG Wealth Advisors's CRBP Position: Q3 2018 in Review

SFMG Wealth Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2018, closing a stake of 370 shares — an estimated $56K sold.

SFMG Wealth Advisors first reported a position in CRBP in Q4 2017 and held it in 3 quarters. The position peaked at $79K in Q4 2017. 77 funds tracked by Wall St. Rank hold CRBP as of Q3 2018.

  • SFMG Wealth Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • SFMG Wealth Advisors sold 370 Corbus Pharmaceuticals shares in Q3 2018, an estimated $56K.
  • SFMG Wealth Advisors first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • SFMG Wealth Advisors's Corbus Pharmaceuticals position peaked at $79K in Q4 2017.
  • 77 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2018.

Based on SFMG Wealth Advisors's 13F filing for Q3 2018, filed 15 Nov 2018.